{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:20:57Z","timestamp":1756992057287},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T00:00:00Z","timestamp":1355875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00246-012-0598-8","type":"journal-article","created":{"date-parts":[[2012,12,18]],"date-time":"2012-12-18T12:29:22Z","timestamp":1355833762000},"page":"213-219","source":"Crossref","is-referenced-by-count":10,"title":["Evolving Management of Pediatric Pulmonary Arterial Hypertension: Impact of Phosphodiesterase Inhibitors"],"prefix":"10.1007","volume":"34","author":[{"given":"Andrew James","family":"Wardle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M. R.","family":"Tulloh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,19]]},"reference":[{"key":"598_CR1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1067\/mtc.2002.125265","volume":"124","author":"AM Atz","year":"2002","unstructured":"Atz AM, Lefler AK, Fairbrother DL et al (2002) Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg 124:628\u2013629","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"Suppl 1","key":"598_CR2","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jacc.2009.04.011","volume":"54","author":"DB Badesch","year":"2009","unstructured":"Badesch DB, Champion HC, Sanchez MA et al (2009) Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 54(Suppl 1):S55\u2013S66","journal-title":"J Am Coll Cardiol"},{"key":"598_CR3","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","volume":"30","author":"RJ Barst","year":"2011","unstructured":"Barst RJ, Oudiz RJ, Beardsworth A et al (2011) Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group: tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 30:632\u2013643","journal-title":"J Heart Lung Transplant"},{"key":"598_CR4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","volume":"125","author":"RJ Barst","year":"2012","unstructured":"Barst RJ, Dunbar I, Gaitan G et al (2012) A randomised double-blind placebo-controlled dose-ranging study of oral sildenfail citrate in treatment naive children with pulmonary arterial hypertension. Circulation 125:324\u2013334","journal-title":"Circulation"},{"key":"598_CR5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCULATIONAHA.111.026591","volume":"125","author":"RJ Barst","year":"2012","unstructured":"Barst RJ, McGoon MD, Elliott CG et al (2012) Childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 125:113\u2013122","journal-title":"Circulation"},{"key":"598_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000088192","volume":"89","author":"D Bassler","year":"2006","unstructured":"Bassler D, Choong K, McNamara P et al (2006) Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 89:1\u20135","journal-title":"Biol Neonate"},{"key":"598_CR7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0140-6736(11)61621-8","volume":"379","author":"RM Berger","year":"2012","unstructured":"Berger RM, Beghetti M, Humpl T et al (2012) Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 379:537\u2013546","journal-title":"Lancet"},{"key":"598_CR8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/adc.88.9.827","volume":"88","author":"WD Carroll","year":"2003","unstructured":"Carroll WD, Dhillon R (2003) Sildenafil as a treatment for pulmonary hypertension. Arch Dis Child 88:827\u2013828","journal-title":"Arch Dis Child"},{"key":"598_CR9","first-page":"78","volume":"22","author":"F Della Torre","year":"2005","unstructured":"Della Torre F, Della Torre E, Di Berardino F (2005) Sildenafil in pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 22:78\u201379","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"598_CR10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","volume":"425","author":"R Derynck","year":"2003","unstructured":"Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF family signalling. Nature 425:577\u2013584","journal-title":"Nature"},{"key":"598_CR11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.acvd.2009.12.001","volume":"103","author":"A Fraisse","year":"2010","unstructured":"Fraisse A, Jais X, Schleich JM et al (2010) Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 103:66\u201374","journal-title":"Arch Cardiovasc Dis"},{"key":"598_CR12","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"JN Galie","year":"2009","unstructured":"Galie JN, Brundage BH, Ghofrani H et al (2009) Tadalafil therapy for pulmonary arterial hypertension. Pulmonary arterial hypertension and response to tadalafil (PHIRST) study group. Circulation 119:2894\u20132903","journal-title":"Circulation"},{"key":"598_CR13","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00431-010-1378-1","volume":"170","author":"A Hawkins","year":"2011","unstructured":"Hawkins A, Langton-Hewer S, Henderson J et al (2011) Management of pulmonary hypertension in down syndrome. Eur J Pediatr 170:915\u2013921","journal-title":"Eur J Pediatr"},{"key":"598_CR14","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1161\/CIRCULATIONAHA.104.473371","volume":"111","author":"T Humpl","year":"2005","unstructured":"Humpl T, Reyes JT, Holtby H et al (2005) Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single drug, open-label, pilot study. Circulation 111:3274\u20133280","journal-title":"Circulation"},{"key":"598_CR15","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","volume":"183","author":"ZC Jing","year":"2011","unstructured":"Jing ZC, Yu ZX, Shen JY et al (2011) Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Efficacy and safety of vardenafil in the treatment of pulmonary arterial hypertension (evaluation) study group. Am J Respir Crit Care Med 183:1723\u20131729","journal-title":"Am J Respir Crit Care Med"},{"key":"598_CR16","doi-asserted-by":"crossref","unstructured":"Karasu-Minareci E, Ozbudak I, Ozbillim G, et al (2012) Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. Sci World J 2012. doi: 10.1100\/2012\/718279","DOI":"10.1100\/2012\/718279"},{"key":"598_CR17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijcard.2004.09.002","volume":"100","author":"AA Karatza","year":"2005","unstructured":"Karatza AA, Bush A, Magee AG (2005) Safety with pulmonary hypertension. Int J Cardiol 100:267\u2013273","journal-title":"Int J Cardiol"},{"key":"598_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1743-6109.2011.02537.x","volume":"9","author":"G Lowe","year":"2012","unstructured":"Lowe G, Costabile R (2012) 10-year analysis of adverse event reports to the food and drug administration for phosphodiesterase type-5 inhibitors. J Sex Med 9:265\u2013270","journal-title":"J Sex Med"},{"key":"598_CR19","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1136\/hrt.2009.182378","volume":"96","author":"S Moledina","year":"2010","unstructured":"Moledina S, Hislop AA, Foster H et al (2010) Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 96:1401\u20131406","journal-title":"Heart"},{"key":"598_CR20","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1164\/rccm.200605-694OC","volume":"174","author":"P Namachivayam","year":"2006","unstructured":"Namachivayam P, Theilen U, Butt WW et al (2006) Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174:1042\u20131047","journal-title":"Am J Respir Crit Care Med"},{"key":"598_CR21","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jacc.2009.04.012","volume":"54","author":"G Simmoneau","year":"2009","unstructured":"Simmoneau G, Robbins IM, Beghetti M et al (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43\u2013S54","journal-title":"J Am Coll Cardiol"},{"key":"598_CR22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","volume":"149","author":"G Simonneau","year":"2008","unstructured":"Simonneau G, Rubin LJ, Galie N et al (2008) Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 149:521\u2013530","journal-title":"Ann Intern Med"},{"key":"598_CR23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.pupt.2007.11.006","volume":"21","author":"RM Spring","year":"2008","unstructured":"Spring RM, Ulrich S, Huber LC et al (2008) Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. Pulm Pharmacol Ther 21:516\u2013521","journal-title":"Pulm Pharmacol Ther"},{"key":"598_CR24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1440-1681.2009.05304.x","volume":"37","author":"X Sun","year":"2010","unstructured":"Sun X, Li Z, Liu Y et al (2010) Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscle cells. Clin Exp Pharmacol Physiol 37:362\u2013367","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"598_CR25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00246-012-0180-4","volume":"33","author":"S Takatsuki","year":"2012","unstructured":"Takatsuki S, Calderbank M, Ivy DD (2012) Initial experience with tadalfil in pediatric pulmonary arterial hypertension. Pediatr Cardiol 33:683\u2013688","journal-title":"Pediatr Cardiol"},{"key":"598_CR26","unstructured":"Torres F, Gupta H, Soto F, et al (2011) Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: the COMPASS-3 Study (abstract). In: ERS Annual Congress 2011"},{"key":"598_CR27","first-page":"73","volume":"43","author":"A Tudor","year":"2005","unstructured":"Tudor A, Mu\u015fat A, Bari M et al (2005) Observations on peripheral microcirculation in young hypertensive patients. Rom J Intern Med 43:73\u201378","journal-title":"Rom J Intern Med"},{"key":"598_CR28","unstructured":"U.S Food and Drug Administration (2012) FDA drug safety communication: FDA recommends against use of Revatio in children with pulmonary hypertension. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm317123.htm . Accessed 11 Mar 2012"},{"key":"598_CR29","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1136\/bmj.e554","volume":"344","author":"B Wirostko","year":"2012","unstructured":"Wirostko B, Trssler C, Hwang L et al (2012) Ocular safety of sildenafil citrate when administered chronically for pulmonary arterial hypertension: results from phase III, randomised, double-masked, placebo-controlled trial and open label extension. BMJ 344:e554","journal-title":"BMJ"},{"key":"598_CR30","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0091270008315315","volume":"48","author":"RE Wrishko","year":"2008","unstructured":"Wrishko RE, Dingemanse J, Yu A et al (2008) Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 48:610\u2013618","journal-title":"J Clin Pharmacol"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-012-0598-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00246-012-0598-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-012-0598-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T14:18:53Z","timestamp":1558707533000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00246-012-0598-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,19]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["598"],"URL":"https:\/\/doi.org\/10.1007\/s00246-012-0598-8","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,19]]}}}